Is Ketamine a psychedelic?

Ketamine sits in an interesting place. Technically, it is classified as a dissociative anaesthetic. But at lower, sub-anaesthetic doses, it produces experiences that most people would recognise as psychedelic: shifts in perception, a loosening of the usual boundaries of self, altered senses of time and space, and sometimes something harder to put into words altogether.

The word psychedelic comes from the Greek: psyche (mind) and deloun (to manifest or reveal). Mind-manifesting. It is a useful definition to hold onto, because it shifts the question away from pharmacology and towards experience. And by that measure, ketamine belongs in the conversation.

Whether it earns the label formally depends on who you ask. Classical psychedelics like psilocybin and LSD act primarily on serotonin receptors in the brain. Ketamine works differently. It blocks NMDA receptors, triggering a surge of glutamate that produces its distinctive dissociative and perceptual effects. Some researchers insist the term psychedelic should be reserved for serotonergic compounds. Others take a broader view, and in clinical practice, that broader view tends to win out.

What matters more, perhaps, is what people actually experience. Patients in ketamine-assisted therapy frequently report things that sound very familiar to those who have worked with other psychedelic medicines: a softening of ego, vivid internal imagery, a sense of connection or meaning, and moments that resist easy description. The journey tends to be somewhat gentler and more dream-like than classical psychedelics, which is part of why it has found a foothold in clinical settings. It is generally shorter-acting, more predictable in its dosing, and already holds a legitimate medical licence, which removes several practical and regulatory barriers.

There is also something happening neurologically that matters therapeutically. Like other psychedelics, ketamine appears to promote neuroplasticity: a temporary opening of the brain to new patterns, new connections, new ways of processing. That window is not permanent, but with skilled therapeutic support, it can be used to do real work.

At Mirabilis Health, we do not use ketamine because it is a shortcut or a workaround. We use it because the evidence supports it, because the experience it offers is genuinely meaningful for many people, and because it allows us to offer something that was not previously available in Northern Ireland: a properly supported, clinically supervised programme where the medicine and the therapy work together.